Drugs that contain Eslicarbazepine Acetate

1. Drug name - APTIOM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9206135 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(3 years from now)

CN101277937A SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

CN101277937B SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

IN200801071P1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

IN263294B SUNOVION PHARMS INC A Process For Preparing (S) Or (R) -10,11-Dihydro-10-Hydroxy-5H-Dibenz[B,F] Azepine-5-Carboxamide
Apr, 2026

(3 years from now)

EP2319836B1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP2319836A1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP1915346A1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP1915346B1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702536 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US10695354 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US10675287 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US9643929 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine Apr, 2026

(3 years from now)

US9763954 SUNOVION PHARMS INC Therapeutical uses of eslicarbazepine Sep, 2028

(5 years from now)

US9566244 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Oct, 2028

(6 years from now)

US10912781 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Oct, 2028

(6 years from now)

US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Apr, 2030

(7 years from now)

US9750747 SUNOVION PHARMS INC Treatments involving eslicarbazepine acetate or eslicarbazepine Aug, 2032

(9 years from now)

Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; treatment of partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine; Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.